Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 87Carcinoma, Non-Small-Cell Lung 78Multiple Myeloma 72Prostatic Neoplasms 66Neoplasms 47Lymphoma 43Leukemia, Myeloid, Acute 42Melanoma 38Neoplasm Metastasis 37Lymphoma, Non-Hodgkin 33Ovarian Neoplasms 32Lung Neoplasms 32Squamous Cell Carcinoma of Head and Neck 31Hematologic Neoplasms 29Leukemia, Lymphocytic, Chronic, B-Cell 28Colorectal Neoplasms 26Triple Negative Breast Neoplasms 23Hodgkin Disease 23Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Myelodysplastic Syndromes 21Sarcoma 20Fallopian Tube Neoplasms 20Pancreatic Neoplasms 19Carcinoma, Renal Cell 19Lymphoma, Follicular 17Leukemia 17Head and Neck Neoplasms 17Glioma 17Urinary Bladder Neoplasms 16Recurrence 16

Interventions

mirdametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neurofibromatoses × 90 days × Clear all
NCT03962543 2026-05-06

ReNeu

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 2 Active not recruiting
114 enrolled 25 charts 1 FDA
CNS

Neurofibroma, Neurofibromatosis 1, Neurofibromatoses, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡